Dr Daniel Krell undertook his oncology training at University College Hospital and The Royal Free Hospital in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, as well as a DPhil in Clinical Medicine at The University of Oxford.
His clinical work focuses on the management of patients with gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours, using chemotherapy, targeted therapy and immunotherapy.
He also manages patients with cancer of unknown primary and is the clinical lead at his institution for this. He also acts as the MDT lead for gastro-oesophageal and hepatobiliary cancer at his institution.
Dr Krell’s DPhil research was undertaken at The University of Oxford's, Wellcome Trust Centre for Human Genetics, and was funded by Cancer Research UK and HCA. Dr Krell’s research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer, with a view to identifying new therapeutic targets in this area. He continues to be involved in clinical research and clinical trials aimed at identifying new cancer therapies, with a focus on gastrointestinal, hepatobiliary and neuroendocrine tumours.
Dr Krell has published several peer-reviewed papers in journals such as Cancer Cell, The British Journal of Cancer and Lancet Oncology, and has submitted and presented abstracts and posters at national and international conferences.
He is a member of the chemotherapy operations group as well as the London cancer expert reference group for acute oncology and cancer of unknown primary.